Skip to Main Content

Paper Details

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
1
2022

Datasets

Release 1.2